Reply to the Letter to the Editor “Anemia of Chronic Kidney Disease: Which Therapeutics Are Available?” Regarding the Article “Anemia in Chronic Kidney Disease: The State of the Art”

Authors

  • Ana Farinha Anemia Working Group Portugal. Lisboa.

DOI:

https://doi.org/10.20344/amp.20651

Keywords:

Anemia/drug therapy, Prolyl-Hydroxylase Inhibitors/therapeutic use, Renal Insufficiency, Chronic/complications

Abstract

N/a.

Downloads

Download data is not yet available.

References

Condeço S, Marques da Silva B. Anemia of chronic kidney disease: which therapeutics are available? Acta Med Port. 2023;36:296-303.

Portugal. Portaria n.º 255/2018. Diário da República, I série, n.º 173 (2018/09/07). p.4707.

Portugal. Despacho n.º 6370/2002. Diário da República, II série, n.º 69 (2002/03/22).

Farinha A, Robalo Nunes A, Mairos J, Fonseca C. Anemia da doença renal crónica: o estado da arte. Acta Med Port. 2022;35:758-64.

US Food & Drug Administration. FDA Briefing Document: Cardiovascular and Renal Drugs Advisory Committee Meeting July 15, 2021. Roxadustat. [consultado 2023 set 12]. Disponível em: https://www.fda.gov/media/150728/download.

Published

2023-10-02

How to Cite

1.
Farinha A. Reply to the Letter to the Editor “Anemia of Chronic Kidney Disease: Which Therapeutics Are Available?” Regarding the Article “Anemia in Chronic Kidney Disease: The State of the Art”. Acta Med Port [Internet]. 2023 Oct. 2 [cited 2024 Jul. 25];36(10):693-4. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/20651

Issue

Section

Letters to the Editor